• Tags: diabetic retinopathy
AOA report analyzes ocular risks of GLP-1RAs
Research

AOA report analyzes ocular risks of GLP-1RAs

Released during the 2025 Optometry’s Meeting, this comprehensive rundown dives into potential rare ophthalmic side effects associated with use—and offers clinical care recommendations.
Earlier diabetes diagnosis may lead to worsening DR progression
Research

Earlier diabetes diagnosis may lead to worsening DR progression

Study identifies mechanisms for the potential protective effect of later diabetes diagnosis on DR severity.
FDA approves Genentech's Susvimo for DR
Products

FDA approves Genentech's Susvimo for DR

First sustained-release delivery system of ranibizumab earns third indication, with injections needed just once every 9 months.
Air pollution exposure leading to more ocular disease cases among adults
Research

Air pollution exposure leading to more ocular disease cases among adults

Myopic eyes demonstrated increased risk of ocular disease with exposure to air pollution.
FDA declines Regeneron's EYLEA HD sBLA for extended dosing
Products

FDA declines Regeneron's EYLEA HD sBLA for extended dosing

Request was for additional extended dosing interval > every 16 weeks; agency makes no mention of request for new indication of macular edema following RVO.
FDA accepts Regeneron's EYLEA HD sBLA for priority review
Products

FDA accepts Regeneron's EYLEA HD sBLA for priority review

Agency sets target action date of Aug. 19 to consider a new indication for macular edema following RVO and expanded monthly dosing.
Settlement paves way for US commercialization of Eylea biosimilar
Products

Settlement paves way for US commercialization of Eylea biosimilar

Biocon Biologic’s YESAFILI (aflibercept-jbvf) now expected to launch in H2 2026 after dismissal of Regeneron’s patent infringement lawsuits.
Hormones may play key role in DR risk among diabetes patients
Research

Hormones may play key role in DR risk among diabetes patients

Surprising findings reveal how sex hormones may secretly influence the risk for diabetic retinopathy.
AAO adds ERG to preferred practice guidelines for DR
Business

AAO adds ERG to preferred practice guidelines for DR

Gold standard for clinical decision-making promotes electroretinography, enabling earlier intervention and personalized care.
 Kodiak Sciences concludes enrollment for phase 3 DR on tarcocimab
Pipeline

Kodiak Sciences concludes enrollment for phase 3 DR on tarcocimab

Anti-VEGF tarcocimab tedromer is under clinical investigation as a mainstay IVT monotherapy with twice-yearly dosing for three retinal indications.
Earlier PPV may benefit vitrectomy among PDR patients
Research

Earlier PPV may benefit vitrectomy among PDR patients

Early PPV associated with improved visual outcomes and fewer severe complications.
Opus Genetics and FDA agree on SPA for phase 3 NPDR gene therapy trial
Pipeline

Opus Genetics and FDA agree on SPA for phase 3 NPDR gene therapy trial

Study’s newly-established primary endpoint will support a potential new drug application submission of APX3300 for market approval.
Avant Technologies and Ainnova to advance low-cost retinal camera with AI software
Business

Avant Technologies and Ainnova to advance low-cost retinal camera with AI software

Newly-formed joint company will develop an exclusive retinal imaging camera to be integrated into Ainnova’s disease detection digital platform.
Cholesterol medication may also reduce DR risk
Research

Cholesterol medication may also reduce DR risk

LENS trial evaluated the cholesterol medication fenofibrate’s potential ability to slow DR.
Eyedaptic introduces AI-powered smart glasses for AMD
Products

Eyedaptic introduces AI-powered smart glasses for AMD

Next-gen device features interactive, generative visual assistant with a built-in camera and hands-free capabilities.
Prevalence of DR is increasing among diabetics, minorities
Research

Prevalence of DR is increasing among diabetics, minorities

New study identifies trends in type 1 and type 2 diabetic retinopathy prevalence.
Topcon and Orbis partner to expand DR screenings in sub-Saharan Africa
Research

Topcon and Orbis partner to expand DR screenings in sub-Saharan Africa

Collaboration utilizes robotic fundus imaging cameras and an AI-based platform that deliver results in mere seconds for Rwanda patients.
SUSVIMO phase 3 data supports sustained efficacy for DR, DME
Products

SUSVIMO phase 3 data supports sustained efficacy for DR, DME

FDA has also accepted Genentech’s sBLA for the sustained-release drug delivery system’s diabetic eye disease indications.
AAO, NANOS respond to study on semaglutide-NAION connection
Research

AAO, NANOS respond to study on semaglutide-NAION connection

Recent research identified substantial risk for NAION development among diabetic and obese patients using the GLP-1 RA.
Semaglutide for diabetes tied to increased NAION risk
Research

Semaglutide for diabetes tied to increased NAION risk

Mass Eye and Ear researchers identify higher incidence among patients taking popular weight loss and Type 2 diabetes drug.